[Boost]

Moody’s and S&P have upgraded the ratings for Sun Pharma following its proposed $11.75 billion acquisition of Organon. The rating agencies attribute this boost to the company's enhanced scale, increased diversification, and improved earnings potential resulting from the deal. Separately, developer Abdullah Kaya expressed frustration regarding the necessity of opening ports to query personal databases, highlighting a common challenge in open-source database management and web development workflows within the current technical landscape.